On or about December 27, 2007 Bederra Corporation completed the acquisition of Diagnos, Inc. in an all-stock transaction. Bederra Corporation issued 15 million restricted common shares of stock for the assets of Diagnosis, Inc.; Diagnos, Inc. will operate as a wholly owned subsidiary of Bederra Corporation. The financial statements issued by the company will reflect the combined financial results.

Diagnos, Inc., a privately held Texas Corporation, is located at 2000 N. Loop W., Suite 100, Houston, Texas, 77018. Diagnosis, Inc. was formed to provide medical diagnostic imaging services utilizing state of the art Positron Emission Tomography technology to detect Cancer, Alzheimer’s, Dementia and Heart Disease. The technology is so new there are only 18 machines in the Houston area serving a population of over 5 million. The technology is proven and accepted by Medicare and all private insurance carriers. The current medical disciplines that use this technology are oncology, neurology, cardiology, and urology.

Graham Williams, President of Bederra Corporation, states, “The acquisition of Diagnos, Inc. is the first of many medical related acquisitions planned to enhance our revenues in the coming years.” Projected gross revenues for fiscal year 2008 are anticipated to be in excess of $2.5 million dollars with profits.

Bederra Corporation issued 15 million restricted shares of common stock to the owners of Diagnosis, Inc.; as of December 31 2007, Bederra Corporation has 28,416,204 shares of common stock outstanding with 6 million shares in the public float.

Safe Harbor Statement

Statements contained in this release, which are not historical facts, may be considered "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and the current economic environment. This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.